1403/01/09
حشمت اله علی نژاد

حشمت اله علی نژاد

مرتبه علمی: استاد
ارکید:
تحصیلات: دکترای تخصصی
اسکاپوس:
دانشکده: دانشکده شیمی
نشانی:
تلفن: 9111144735

مشخصات پژوهش

عنوان
Application of FT-IR spectroscopy on breast cancer serum analysis
نوع پژوهش
JournalPaper
کلیدواژه‌ها
FT-IR spectroscopy Breast cancer Serum PCA-LDA analysis
سال
2017
مجله SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
شناسه DOI
پژوهشگران Fatemeh Elmi ، Afshin Fayyaz Movaghar ، Heshmatollah Alinezhad ، novin nikbakhsh ، Maryam Mitra Elmi

چکیده

Breast cancer is regarded as the most malignant tumor among women throughout the world. Therefore, early detection and proper diagnostic methods have been known to help save women's lives. Fourier Transform Infrared (FT-IR) spectroscopy, coupled with PCA-LDA analysis, is a new technique to investigate the characteristics of serum in breast cancer. In this study, 43 breast cancer and 43 healthy serum samples were collected, and the FTIR spectra were recorded for each one. Then, PCA analysis and linear discriminant analysis (LDA) were used to analyze the spectral data. The results showed that there were differences between the spectra of the two groups. Discriminating wavenumbers were associated with several spectral differences over the 950‐1200 cm‐1(sugar), 1190‐1350 cm‐1 (collagen), 1475‐1710 cm‐1 (protein), 1710‐1760 cm‐1 (ester), 2800‐3000 cm‐1 (stretching motions of –CH2 & ‐CH3), and 3090‐3700 cm‐1 (NH stretching) regions. PCA-LDA performance on serum IR could recognize changes between the control and the breast cancer cases. The diagnostic accuracy, sensitivity, and specificity of PCA-LDA analysis for 3000‐3600 cm‐1 (NH stretching) were found to be 83%, 84%, 74% for the control and 80%, 76%, 72% for the breast cancer cases, respectively. The results showed that the major spectral differences between the two groups were related to the differences in protein conformation in serum samples. It can be concluded that FT-IR spectroscopy, together with multivariate data analysis, is able to discriminate between breast cancer and healthy serum samples.